Q3 2024 Biomx Inc Earnings Call Transcript
Key Points
- BiomX Inc (PHGE) completed patient enrollment for the phase two trial of BX 201 for diabetic foot osteomyelitis, with topline results expected in Q1 2025.
- The company received additional funding from the US Defense Health Agency, bringing total non-dilutive funding for the DFO trial to $36.8 million.
- BX 201 has the potential to transform treatment for diabetic foot osteomyelitis, addressing antibiotic resistance and biofilm challenges.
- Positive safety and efficacy results for BX 004 were presented at major conferences, strengthening confidence in its potential for cystic fibrosis treatment.
- BiomX Inc (PHGE) has sufficient cash reserves to fund operations into Q4 2025, supported by a $50 million private placement financing in March 2024.
- Manufacturing delays for BX 004 have pushed the expected topline results for the phase two B study to the first half of 2026.
- Research and development expenses increased to $7.3 million in Q3 2024, up from $5.6 million in the same period in 2023.
- General and administrative expenses rose to $3.2 million in Q3 2024, compared to $2.2 million in Q3 2023, due to the acquisition of Adaptive Phage Therapeutics.
- The company recognized a goodwill impairment expense of $801,000 related to the 2024 acquisition of Adaptive Phage Therapeutics.
- Net cash used in operating activities increased significantly to $30.7 million for the nine months ended September 30, 2024, compared to $15 million in the same period in 2023.
Greetings and welcome to the Biomx third quarter, 2024 financial results conference call (Operator Instructions)
It is now my pleasure to introduceMarina Wolfson, Chief Financial Officer. Thank you. You may be good.
Thank you and welcome to the Biomx conference call to review the company's third quarter, 2024 financial results and provide an update on our business and programs. Later today, we will file the quarterly report on form 10-Q with the Securities and Exchange Commission.
In addition, the press release became available at 6:30 a.m. Eastern time today and can be found on our website at Bionics dotcom.
A replay of this call will also be available on the investors section of our website.
As we begin, I'd like to review the safe harbor provision.
All statements on this call that are not factual historic statements may be deemed forward-looking statements. For instance, we're using forward-looking statements when we discuss on the conference call, the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
